Some Products May Appear Restricted
To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.
If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/ca/en/login/register)
If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation; additional documentation will be requested for these items prior to shipment.
- Size:100 Assays
- Cat. no.:103010-666
- Storage Temperature:– 20 °C
- Includes:The assays can be performed in a convenient 96-well microplate format, kit includes essential components and detailed protocol and references
- Supplier No.:AS-72225
BACE2 (β-Secretase-2, Memapsin-1) belongs to the family of transmembrane aspartic proteases
The SensoLyte® 520 BACE2 Assay Kit is a homogeneous assay that can be used to detect the activity of enzyme and for screening of BACE2 inhibitors. It contains a QXL® 520/ HiLyte™ Fluor488 FRET substrate, derived from a peptide sequence surrounding cleavage site of BACE2. QXL® 520 quenches HiLyte™ Fluor488 fluorescence in the intact FRET peptide. Active BACE2 cleaves FRET substrate into two separate fragments resulting in the release of HiLyte™ Fluor488 fluorescence that can be monitored at excitation /emission= 490/520 nm. The long wavelength fluorescence of HiLyte™ Fluor488 is less interfered by the autofluorescence of components in biological samples and test compounds.
BACE2 has approximately 75% homology with BACE1 (β-Secretase-1) and is similar in that both cleaves Amyloid Precursor Protein (APP) at β-site generating N-terminal part of beta-Amyloid peptide. Unlike BACE1 that is highly expressed in pancreas and brain tissue, BACE2 is more widespread and can be found in many peripheral tissues at higher levels compared to BACE1. BACE2 is one of the highest efficiency beta-amyloid peptide degrading enzyme that is less active only to insulin degrading enzyme (IDE); therefore, targeting BACE2 is considered a potential therapeutic strategy for the prevention and treatment of Alzheimer's disease.